The global antiarrhythmic medicine sales show significant variability across countries. Italy leads with $90.1 million in value, despite a slight decline in 2023 by -1.05%. Canada follows at $17.4 million, with a -2.35% decrease. Sweden and Austria, generating $6.6 million and $6.0 million respectively, experienced declines of -8.34% and -4.62%. Norway and Ireland both saw sales of $3.6 million, with Norway experiencing a -7.79% drop and Ireland a modest -0.55% decline. Latvia was an outlier with a positive growth of 10.35%, reaching $1.8 million in sales. New Zealand, Estonia, and Luxembourg saw significant reductions, with values of $1.1 million, $0.5 million, and $0.4 million, and respective declines of -17.62%, -11.09%, and -7.79% in 2023.
Future trends to watch for include potential market recovery in currently declining regions due to advancements in medical technology and increasing awareness of cardiac health. Significant growth is expected in countries with already positive trends like Latvia. Additionally, emerging markets in developing countries could see increased demand as healthcare access improves.
Top countries in Antiarrhythmic Medicine Sales by Country
| # | 10 Countries | Million US Dollars | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Italy | 90.1 | 2023 | +4.28% | -1.05% | View data |
| 2 | 2 Canada | 17.4 | 2023 | -3.33% | -2.35% | View data |
| 3 | 3 Sweden | 6.6 | 2023 | +20% | -8.34% | View data |
| 4 | 4 Austria | 6 | 2023 | -3.23% | -4.62% | View data |
| 5 | 5 Norway | 3.6 | 2023 | 0% | -7.79% | View data |
| 6 | 6 Ireland | 3.6 | 2023 | 0% | -0.55% | View data |
| 7 | 7 Latvia | 1.8 | 2023 | +5.88% | +10.35% | View data |
| 8 | 8 New Zealand | 1.1 | 2023 | -8.33% | -17.62% | View data |
| 9 | 9 Estonia | 0.5 | 2023 | -16.67% | -11.09% | View data |
| 10 | 10 Luxembourg | 0.4 | 2023 | 0% | -7.79% | View data |
